In this exploratory trial, low-frequency right DLPFC rTMS monotherapy reduced anxiety symptoms more than low-dose sertraline monotherapy during the initial 4-week period, whereas the combination therapy achieved efficacy comparable with sertraline monotherapy. These preliminary findings suggest rTMS may serve as an alternative for treatment-naïve patients with GAD, but larger confirmatory trials are required.
Song et al. (Thu,) studied this question.